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Abstract
Background: Neurotrophins (NTs) are able to activate lymphocytes and fibroblasts; they can modulate angiogenesis and
sympathic vascular function. Thus, they can be implicated in the three pathogenic processes of systemic sclerosis (SSc). The
aims of this study are to determine blood levels of Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF)
and Neurotrophin-3 (NT-3) in SSc and to correlate them with clinical and biological data.
Methods: Serum samples were obtained from 55 SSc patients and 32 control subjects to measure NTs levels by ELISA and to
determine their relationships with SSc profiles.
Findings: Serum NGF levels were higher in SSc patients (288.266170.34 pg/mL) than in control subjects (170.34650.8 pg/
mL, p,0.001) and correlated with gammaglobulins levels and the presence of both anti-cardiolipin and anti-Scl-70
antibodies (p,0.05). In contrast, BDNF levels were lower in SSc patients than in controls (1121.96158.1 vs 1372.96190.9 pg/
mL, p,0.0001), especially in pulmonary arterial hypertension and diffuse SSc as compared to limited forms (all p,0.05). NT-
3 levels were similar in SSc and in the control group (2657.262296 vs 2959.362555 pg/mL, NS). BDNF levels correlated
negatively with increased NGF levels in the SSc group (and not in controls).
Conclusion: Low BDNF serum levels were not previously documented in SSc, particularly in the diffuse SSc subset and in
patients with pulmonary hypertension or anti-Scl-70 antibodies. The negative correlation between NGF and BDNF levels
observed in SSc and not in healthy controls could be implicated in sympathic vascular dysfunction in SSc.
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Introduction
Systemic sclerosis (SSc) is a chronic connective tissue disease
characterized by at least 3 pathogenic processes: immunological
abnormalities, micro-vascular dysfunction and fibrosis [1].
Neurotrophins (NTs) belong to a family of growth factors that
control the development, growth and apoptotic death of neurons
and astrocytes [2]. Accumulating evidences suggest that NTs,
especially Nerve Growth Factor (NGF) and Brain-Derived
Neurotrophic Factor (BDNF), participate in inflammatory re-
sponses, including the modulation and regulation of immune
functions in inflammatory and autoimmune diseases [2]. NGF
serum levels are increased in various autoimmune diseases such as
systemic lupus erythematosus and rheumatoid arthritis [3].
Increased NGF and BDNF plasmatic levels have also been
recently reported in primary Sjo ¨gren’s syndrome in correlation
with systemic activity and B and T cell activation [4].
Neurotrophins could also be implicated in the generalized
microangiopathy observed in SSc. Indeed, angiogenesis, endothe-
lial cell activation, apoptosis and sympathetic vasoconstriction are
modulated by these neuropeptides. NGF promotes angiogenesis
and synthesis of angiogenic factors such as Vascular Endothelial
Growth Factor (VEGF) [5]. As recently evidenced, BDNF can
induce angiogenesis in ischemic tissues [6]. In acute coronary
syndromes, ischemic tissues contain increased BDNF levels that
correlate with inflammation and oxidative stress whereas serum
levels are decreased [7]. Furthermore, pulmonary expression of
p75
NTR, the low affinity NT receptor, regulates endothelial
susceptibility to endothelin-1 [8]. Thus, NTs could regulate
agonist-induced pulmonary vasoconstriction [8].
NGF is able to induce both fibroblast proliferation and collagen
production [9]. These pro-fibrogenic properties of NGF are
mediated by transforming growth factor-beta (TGFb) [10,11], a
key cytokine in the pathogenesis of SSc related fibrosis [12].
However, data concerning the implication of NTs in SSc are
sparse and restricted to NGF. Skin NGF expression is increased in
SSc patients compared to healthy controls, especially in the early
stages of the disease [13]. The same group reported increased
blood NGF levels in SSc, especially in the diffuse subset of the
disease and in patients with prominent articular disease [14].
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13918The aim of the present study was to evaluate serum levels of
NGF, BDNF and NT-3 in patients with SSc and to investigate
their relationship with clinical and immunological data.
Materials and Methods
Patients and control population
Fifty five consecutive SSc patients including 49 women (median
age 54.2612.5 years), all fulfilling the revised American College of
Rheumatology (ACR) criteria for SSc were included in a cross
sectional study in two French SSc competence centers by using the
same screening protocol [15]. Mean disease duration at time of the
study was 5.563.3 years. Disease stages were defined as suggested
by Medsger and Steen: early limited SSc, disease duration ,5
years; intermediate/late limited SSc, disease duration $ 5 years,
early diffuse SSc, disease duration ,3 years and intermediate/late
diffuse SSc, disease duration $ 3 years [16].
Patients with evolutive neoplastic disorders or depression
were excluded in order to avoid interferences in serum NTs levels
[17].
The control population consisted of 32 age- and sex-matched
healthy volunteers. Informed consent was obtained from all
patients and control subjects who participated in the study, which
was approved by the local ethic review board ‘‘Comite ´ d’e ´thique
de la commission d’e ´tablissement du CHU de Limoges’’ directed
by Dr G Terrier (35-2009-17).
Clinical feature
The disease was classified as diffuse (dSSc) or limited SSC (lSSc)
according to the degree of skin involvement [18]. Four patients
have anti-RNP Ab and presented with an overlap syndrome, with
clinical features evoking lupus erythematosus in 3 cases and
polymyositis in one case. The diagnoses of each disease
component were determined according to ACR criteria.
A clinical profile was determined in every SSc patient (Table 1).
Skin involvement was measured by the modified Rodnan skin
score on a scale of 0-51 [19]. The presence of fingertip ulcers at
the time of blood sampling and the existence of previous digital
ulcers were systematically recorded. Lung disease was assessed by
pulmonary function tests, annual X-rays (n=55) and computed
tomography scans (n=11) performed within 12 month before
blood sampling. For the interpretation of the pulmonary function
tests, FVC (liters, percentage of predicted forced vital capacity),
DLCO (CO ml/min/mmHg and percentage of predicted capacity
of carbon monoxide), DLCO/alveolar volume values (percentage
of predicted) and 6 minutes walk test (meters and percentage of
predicted) were measured and compared to those obtained 6 to 12
months earlier. Pulmonary arterial hypertension (PAH) was
defined by a mean pulmonary artery pressure .25 mm Hg at
right heart catheterization. Joint involvement was recorded as
positive when there was objective evidence of tender or swollen
joints, or both. Disease severity was scored by the Medsger’s index
[20].
Concomitant treatment of SSc patients included angiotensin-
converting enzyme inhibitors (n=14), calcium channel blockers
(n=43), endothelin inhibitors (n=6), aspirin (n=12) and statins
(n=12). Eight patients had cyclic intravenous iloprost infusions for
severe Raynaud’s phenomenon within the six-month period before
blood sampling. Fifteen patients were receiving immunomodulat-
ing drugs at the time of blood sampling: low doses of
corticosteroids (n=10, mean 1166.3 mg/day), hydroxychloro-
quine (n=5), methotrexate (n=5) cyclophosphamide (n=2) and
mycophenolate mofetil (n=1).
Measurement of autoantibodies gammaglobulins and
neurotrophins levels
Anti-nuclear, anti-centromere and anti-Scl70 antibodies (Ab)
were characterized by immunofluorescence on HEp2 cells (The
Binding Site, Saint Egre `ve, France) and by ELISA (Phadia, Saint
Quentin Yvelines, France). Anti-cardiolipin Ab were measured by
ELISA (Ingen, Chilly Mazarin, France).
Total serum gammaglobulins were measured by serum protein
immunoelectrophoresis.
Serum NGF, BDNF and NT3 levels were measured using
commercialELISAkitsaccordingtothemanufacturer’sinstructions
(NGF EmaxH ELISA,BDNF EmaxH ELISA,NT-3 ELISA,Promega,
Charbonnie `res, France). All assays were performed in duplicate and
the data are presented as pg/mL. Detection limits were 15 pg/mL
for BDNF and 4 pg/mL for NT-3 and NGF. Coefficients of
variability for the individual samples run in the ELISAs were 0.99,
0.94 and 1.17 for NGF, BDNF and NT3, respectively.
Table 1. Clinical, immunological profiles and functional
respiratory tests characteristic of patients with systemic
sclerosis (SSc).
Clinical characteristics
Age, y(mean 6 sd) 54.5612
Female, n(%) 43 (93)
Classification of scleroderma spectrum of
disease, n( % )
Diffuse scleroderma 9 (19)
Limited scleroderma 33 (72)
Overlap syndrome 4 (9)
Skin involvement, Rodnan score (mean 6 sd) 9.3 67.5
Digital ulcers, n( % )
evolutive 5 (11)
previous 15 (33)
Articular involvement, n( % ) 15 (33)
Pulmonary fibrosis, n( % ) 1 (2)
Pumonary hypertension, n( % ) 2 (4)
associated with pulmonary fibrosis 1 (2)
isolated 1 (2)
Digestive complications, n( % ) 18 (39)
Associated Sjo ¨gren syndrome, n( % ) 9 (19)
Functional respiratory tests characteristics
FVC (liters mean 6 sd; % mean 6 sd) 3.4560.89 110616.2
DLCO (CO ml/min/mmHg mean 6 sd;
% of predicted)
18.664.47 76.5613.5
DLCO/VA (% of predicted) 88.7615.4
6 month-previous DLCO/VA (% of predicted) 86.2615.9
6 minutes walk test (meters mean 6 sd;
% of predicted)
440.45697.8 84.4611.2
Immunological characteristics
Anti-nuclear Ab, n( % ) 44 (96)
Anti-Scl70 Ab, n( % ) 3 (7)
Anti-centromere Ab, n( % ) 33 (71)
Anti-cardiolipin Ab, n( % ) 8 (17)
FVC: forced vital capacity, DLCO: diffusing lung factor for carbon monoxide,
DLCO/VA diffusing capacity divided by the alveolar volume. sPAP: Systolic
pulmonary artery pressure at right heart catheterism. Ab: antibodies.
doi:10.1371/journal.pone.0013918.t001
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Expression of intracellular BDNF by T and B lymphocytes was
assessed by flow cytometry in 5 SSc patients and 5 controls. Whole
blood cells were stained with either phycoerythrin (PE)-cyanin (Cy)
7-conjugated anti-CD3 or anti-CD19 antibodies (Ab) for 15 min
at room temperature. After red blood cell lysing (Immunoprep,
Beckman Coulter, France), white blood cells were fixed,
permeabilized (Intraprep, Beckman Coulter, France) and incubat-
ed at room temperature for 30 min with mouse anti-BDNF Ab
(1/100; Santa Cruz Biotechnology, France) in Phosphate Buffered
Saline (PBS) containing 1% Bovine Serum Albumin. After two
washes in PBS, mAb were revealed using Alexafluor 488-
conjugated goat anti-mouse IgG Ab (10 mg/mL; Invitrogen,
France) for 30 min at 4uC. Cells stained with mouse isotypic
immunoglobulins (Santa Cruz Biotechnology, France) were used
as controls to determine background and positivity thresholds.
After washing twice in PBS, cells were suspended in PBS and
analyzed with a flow cytometer (FacsCanto
TM II).
Statistical analysis
The results were expressed as means 6 standard deviations.
p values #0.05 were considered significant. One-way analysis of
variance (ANOVA), chi-square tests and Mann-Whitney tests were
used when appropriate. To search for correlations between serum
NTs levels and clinical and other biological data, linear regression
analysis was used and p-values determined by Spearman’s rank
correlation test.
Results
Variations in NTs expression in SSc
Serum NGF levels were higher in SSc patients (288.26
6170.34 pg/mL) than in healthy controls (170.34650.8 pg/mL,
p,0.0001) (Figure 1A) whereas BDNF levels were lower (1121.9
6158.1 vs 1372.96190.9 pg/mL) (Figure 1B). Serum NT-3 levels
were similar in SSc and in controls (2657.262296 vs
2959.362555 pg/mL, NS) (Figure 1C).
The lowest BDNF concentrations were those of patients affected
with dSSc (1045.676202.8 pg/mL), as compared with lSSc
patients (11466126.8 pg/mL, p=0.03) (Figure 1D). In contrast,
serum NGF levels were similar in patients with dSSc (346.16
6210 pg/mL), lSSc (271.46136.5 pg/mL) and overlap syndrome
(195.5652 pg/mL).
To examine whether the variation of NGF and BDNF is a
feature of both early and intermediate/late stages of the disease,
serum samples were analyzed according to disease duration. In all
subgroups of patients defined by this criterion, levels of BDNF
were significantly reduced than in healthy controls (BDNF early
dSSc 1041633.8 and late dSSc 1067.26182 pg/mL, NS) and
(BDNF early lSSc 1140.96151.5 and late lSSc 1144.846116.6,
NS) vs controls (1372.96190.9 pg/mL, all p,0.003).
NGF levels were also similar in early (204.9653.4 pg/ml) and
late dSSc (440.16354.7 pg/mL, NS) as well as in lSSc
(2606138.5 pg/mL) and late lSSc (249.86101.1 pg/mL, NS).
NGF and BDNF balance
A strong negative correlation was observed between reduced
BDNF levels and increased NGF concentrations in the whole SSc
group (r=20.33, p=0.01, Figure 2A), in contrast to the lack of
any correlation between these levels in the control group
(r=20.13, NS, Figure 2B). No correlation could be observed
between NT-3 serum levels and NGF and BDNF concentrations
either in the SSc group (NGF r=0.11, NS; BDNF r=0.05, NS) or
in the controls (NGF r=0.06, NS; BDNF r=0.09, NS).
Neurotrophins and SSC clinical profile
Whereas BDNF levels were reduced in the subgroup of patients
with PAH (922.86235.6 vs 1135.86145.4 pg/mL in the absence
Figure 1. (A) Nerve Growth Factor (NGF), (B) Brain-Derived Neurotrophic Factor (BDNF) and (C) Neurotrophin-3 (NT-3)
concentrations measured by ELISA in systemic sclerosis (SSc) patients compared to healthy controls (Controls) (Mann-Whitney
tests). The boxes represent the 50
th percentiles while the bars outside the boxes show the 10
th and 90
th percentiles (N); the horizontal grey lines
represent median values. (D) BDNF serum levels in overlap syndrome (white box), limited SSc (lSSc, grey box) and diffuse SSc (dSSc grey dotted box)
(Mann-Whitney tests).
doi:10.1371/journal.pone.0013918.g001
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similar BDNF decreased serum levels (893.9, 898 and 1130 pg/
mL, respectively). In contrast, NGF concentrations were similar in
patients with or without PAH (393.26143.8 vs 293.66169.8 pg/
mL, NS).
BDNF levels were not significantly different in patients with
(1072.4695.7 pg/mL) and without (11286163.8 pg/mL) finger-
tip ulcers (NS). Similarly, there was no correlation between NGF
levels and the presence of fingertip ulcers.
The presence of articular involvement or digestive complica-
tions did not influence serum levels of NGF, BDNF and NT-3.
NGF, NT-3 and BDNF concentrations were also similar in SSc
patients with or without secondary Sjo ¨gren syndrome. No
correlation of NGF, BDNF and NT-3 levels with the Rodnan
skin score was found either.
BDNF levels were lower in patients with severe (according to
Medsger’s classification) SSc (1055.16127.8 pg/mL) than in those
with mild forms (stade 2, 1162.86104 pg/mL, p=0.05). In
contrast, NGF and NT-3 levels were similar in all Medsger’s
classification groups.
A significant correlation between BDNF and FVC (r=0.39,
p=0.02) (Figure 3) was found in the lSSc group. There were no
significant correlation between serum NTs levels and carbon
monoxide diffusion capacity, DLCO/VA or 6-minutes walk tests.
Declines of DLCO/VA or 6-minutes tests observed during a 6
months follow-up failed to correlate with serum NTs levels also.
Serum NGF, BDNF and NT-3 concentrations were similar in
SSc patients whatever they were treated or not by angiotensin-
converting enzyme inhibitors, calcium channel blockers or statins.
NGF serum concentrations tended to be slightly higher in patients
receiving aspirin (347.96246.1 pg/mL) than in those without
platelet aggregation-inhibiting drug (2616122.7 pg/mL, p=0.08,
NS). NGF and BDNF levels were also similar in SSc patients
with or without endothelin inhibitors. However in the subgroup
of patients with active or previous digital ulcers, NGF levels
were reduced in the 5 patients given endothelin inhibitor
therapy (215.46115.9 pg/mL) as compared to the 19 others
(313.2689 pg/mL, p=0.04). Disease-modifying drugs, except
hydroxychloroquine did not affect serum NTs levels; NT-3
levels were higher in SSc patients with than without
(4555.663933.3 vs 2474.562031.6 pg/mL, p=0.05) hydroxy-
chloroquine, an immuno-modulative drug prescribed for severe
articular manifestations in 80% of the cases.
Neurotrophins and immunological profile
Patients with anti-Scl-70 antibodies showed significantly high
NGF levels (408.36241.4 vs 2626122.2 pg/mL, p=0.008). NGF
levelswere alsoincreased inpatients withanti-cardiolipin antibodies
(408.56262 vs 264.2699.2 pg/mL, p=0.008) (Figure 4A) and
correlated positively with serum gammaglobulin levels (r=0.42,
p=0.03) (Figure 4B).
BDNF production by B and T cells
Intracellular production of BDNF by B and T lymphocytes
estimated by flow cytometry was similar in SSc patients and
controls (mean fluorescence intensity of B cells 3.261.6 vs
2.361.1, NS and T cells 3.760.8 vs 2.961.5, NS).
Figure 2. (A) Correlation between Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) levels in (A) SSc
patients (grey circles) and (B) healthy controls (white circles). The linear regression curve and coefficient of determination given by the
analysis of variance are both represented. Each point represents an individual patient and a healthy control. r defines the coefficient of determination
given by the analysis of the variance table. p-values were determined by Spearman’s rank correlation test.
doi:10.1371/journal.pone.0013918.g002
Figure 3. Correlation between Brain-Derived Neurotrophic
Factor (BDNF) concentrations and forced vital capacity in
limited SSc group (lSSc, grey circles). Each point represents an
individual patient. r defines the coefficient of determination given by
the analysis of variance table. p-value was determined by Spearman’s
rank correlation test.
doi:10.1371/journal.pone.0013918.g003
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The present study documents the yet unreported finding of
reduced serum BDNF levels in SSc, particularly in the diffuse SSc
subset, as well as in patients with severe forms or pulmonary
hypertension. We confirm the increase of serum NGF concentra-
tions previously reported in SSc [14]. Interestingly, NGF and
BDNF levels correlated negatively in SSc patients and not in
healthy controls. Although NT-3 has been recently shown to be
involved in cardiovascular diseases [21], the present data fail to
document its implication in SSc
The present results confirmed previous reports [13,14,22] that
circulating levels of NGF are increased in SSc. The persistence of
high serum NGF levels in intermediate-late forms of SSc strongly
suggests of an implication of NGF in disease pathogeny
independently of the disease duration. Although enhanced dermal
levels of NGF reflect skin involvement in SSc, previous data and
the present study suggest that increased serum NGF levels do not
reflect skin or pulmonary fibrosis in SSc [14]. Indeed, no statistical
correlation between the Rodnan score and serum NGF levels
could be found. Whereas NGF production in the skin could reflect
local inflammatory processes and fibrosis, we hypothesize that
enhanced serum levels are a consequence of the autoimmune
aspect of SSc, especially B cell chronic activation. Indeed, NGF
levels are increased in SSc as well as in various others autoimmune
disease such as lupus erythematosus, rheumatoid arthritis and
primary Sjo ¨gren’s syndrome [3,4,23–25]. NGF, produced by
activated B and T cells, is involved in the maintenance of
immunological memory B cells and it can provide a CD40-
independent signal for immunoglobulin production [26,27]. We
herein evidence a statistical association between increased NGF
levels and anti-Scl-70 and anti-cardiolipin Ab. We also confirmed
the correlation between serum NGF concentrations and gamma-
globulins levels, as previously demonstrated in primary Sjo ¨gren’s
syndrome [4]. Altogether, theses findings suggest an involvement
of NGF in the B cell chronic activation in SSc.
Immunomodulating drugs did not affect NGF and BDNF levels
in SSc. However, data concerning the influence of corticosteroid
and/or immunosuppressive drugs on systemic levels of NGF and
BDNF in autoimmune diseases are contradictory. Whereas serum
NGF levels can be down-regulated by corticosteroid in asthma
[28], immunomodulating drugs do not appear to reduce NGF
levels in rheumatoid arthritis or primary Sjo ¨gren’s’s syndrome
[4,29]. The same discrepancy was reported for BDNF in the same
diseases [28,30]. Although pro-inflammatory cytokines play a role
in promoting NT secretion, other mechanisms are probably
involved in NGF and BDNF release in autoimmune diseases. High
serum NT-3 levels in patients receiving hydroxychloroquine are
intriguing. No previous report deals with NT-3 modulation by
anti-malarial drugs.
Low BDNF levels were not previously reported in SSc. They are
likely unrelated to the immune component of SSc. Indeed, serum
BDNF levels have been reported to be increased in autoimmune
diseases such as rheumatoid arthritis and primary Sjo ¨gren’s
syndrome independently of immunosuppressive treatment [4,29].
No previous reports deal with serum BDNF levels in skin fibrosis;
accordingly, BDNF serum levels did not correlate with Rodnan
skin score in the present study. Therefore, we hypothesize that
decreased BDNF levels do not reflect skin fibrosis in SSc.
Serum BDNF concentrations reflected his production by
various cell types including both endothelial cells [31] and
circulating lymphocytes [4,32]. The production of BDNF by
normal B and T lymphocytes is also modulated by cell activation
[4,33]. Local production of BDNF as well as the expression of its
high affinity receptor TrkB is also enhanced in synovitis in
autoimmune disease [34,35]. However, BDNF production by B
and T lymphocytes was similar in SSc patients and controls.
Therefore, decreased BDNF concentrations are unlikely to reflect
a direct modulation of lymphocytic BDNF production in SSc.
The decreased BDNF levels in SSc patients could be related to
microvascular disease and oxidative stress. BDNF and his receptor
TrkB are expressed by endothelial cells and vascular smooth cells
of capillaries and arteries [36,37]. A reduced BDNF synthesis by
endothelial cells and the binding of serum BDNF to activated
endothelial cells that express the tropomyosin receptor kinase B
(TrkB) might play a role [38]. BDNF is implicated in vascular
development and enhances the survival of vascular endothelial
cells [37]. It enhances vascular flow and regulates revasculariza-
tion of ischemic tissues also [39]. In vitro effects of BDNF on
endothelial cells are comparable to those observed with VEGF
Figure 4. (A) Nerve Growth Factor (NGF) concentrations (ELISA) in patients with (acl+) or without (acl-) anti-cardiolipin Ab (Mann-
Whitney test). The boxes represent the 50
th percentiles while the bars outside the boxes show the 10
th and 90
th percentiles (N); the horizontal grey
lines represent median values. (B) Correlation between Nerve Growth Factor (NGF) concentrations and gammaglobulins levels. The linear regression
curve and coefficient of determination given by the analysis of variance are both represented. p-value was determined by Spearman’s rank
correlation test.
doi:10.1371/journal.pone.0013918.g004
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acute coronary syndrome [7,40]. In addition, increased oxidative
stress decrease serum BDNF concentrations [41,42]. The positive
correlation between serum BDNF levels and forced vital capacity
could also reflect the potential link between this NT and oxidative
stress. Forced vital capacity is known to decrease with enhanced
oxidative stress in SSc [43,44]. Furthermore, BDNF-induced
activation of TrkB signaling in vivo promotes prostacyclin
biosynthesis by cerebral arteries [45]. Altogether, decreased BDNF
levels observed in SSc could reflect vascular damages. This
hypothesis may be supported by the fact that the lowest levels of
BDNF in this study were observed in the 5 patients with PAH.
The present paper reports on the intriguing finding that
decreased BDNF and increased NGF levels correlate both in
early and intermediate/late forms of SSc, which suggests a
potential physiopathological role of this dysbalance. Such a serum
NGF/BDNF balance is not observed normally nor in psycholog-
ical stress, depression, autoimmune diseases or acute coronary
syndrome [4,7,29,46]. This BDNF/NGF balance abnormality
observed in SSc patients might be a marker of chronic vascular
dysfunction and oxidative stress. It is clear that NTs play an
important role in maintaining normal vascular tone, oxidative
homeostasis and in the regulation of the response of both
endothelial and vascular smooth muscle cells to injury [35,37].
Exogenous BDNF co-infused with NGF-receptor blocking Ab
induces a marked vasoconstriction and perivascular inflammation
[47], in accordance with the fact that NGF exerts a protective
function in vascular control whereas BDNF alone has no
significant effect on vascular diameter [47]. NGF reduces oxidative
stress-induced injury by up-regulating antioxidants and oxygen
free radical scavengers such as catalase, glutathione peroxidase
and superoxide dismutase [48]. Hence, NGF can protect against
post-ischemic dysfunction of sympathetic innervations and ische-
mia-reperfusion myocardial injury [49,50]. In the present study,
the relationship between oxidative stress and enhanced NGF levels
could be deduced from the statistical relationship between NGF
levels and anti-cardiolipin antibodies, which reflect vascular
damage in SSc [51,52]. The normalization of NGF levels in the
5 patients undergoing endothelin inhibitor therapy reinforces the
assumption of the relationship between NGF levels and oxidative
stress in SSc [53].
Altogether, reduced serum BDNF levels associated with
vascular lesions and oxidative stress in SSc could be counterbal-
anced by ‘‘protective’’ increased NGF levels. Further studies and
animal models should help to further elucidate the pathological
relevance of NGF/BDNF balance, as well as uncover the precise
mechanism of this interaction in the multifaceted pathogenesis of
SSc.
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